Navigation Links
Study finds survival rates from gastrointestinal tumors improving among African-Americans
Date:7/14/2009

CHICAGO (July 14, 2009) New research published in the July issue of the Journal of the American College of Surgeons reveals that African Americans with gastrointestinal stromal tumors (GIST), a rare cancer that begins in the wall of the gastrointestinal tract, now have survival rates equivalent to those of Caucasians. Prior to 2000, African Americans were more likely to develop GIST and less likely to undergo surgical treatment for this type of cancer.

Racial disparities in survival rates have been demonstrated for a number of cancers, typically due to unequal access to care. Through the National Institutes of Health and Healthy People 2010, a national health promotion and disease prevention initiative, the federal government has set forth goals to explore, account for and minimize these disparities.

"Over the last decade, racial gaps in the treatment of GIST appeared to have closed," said Michael Cheung, MD, DeWitt Daughtry Family Department of Surgery, University of Miami, Miller School of Medicine. "Both perioperative and long-term survival have improved among African Americans."

"Our study suggests that better diagnosis and increased use of surgery which still provides the best chance for cure have contributed to improvements in care for African Americans," said Leonidas G. Koniaris, MD, FACS, associate professor of surgery, DeWitt Daughtry Family Department of Surgery, University of Miami Miller School of Medicine, and surgical oncologist at Sylvester Comprehensive Cancer Center at UM. "In addition, increased access to new targeted therapies through medication assistance programs may be helping to eliminate racial disparities in cancer treatment."

A statistical analysis was performed using the Surveillance, Epidemiology and End Results (SEER) database that identified 3,795 patients diagnosed with GIST and other intestinal mesenchymal tumors between1992 to 2005. Patient demographics showed 72.2 percent Caucasians, 15.6 percent African Americans, and 9.1 percent Hispanics. Survival was calculated from the time of initial diagnosis to the date of last contact or death.

Both perioperative and long-term survival had improved among African Americans since 2000. In patients diagnosed before the year 2000, 30-day surgical mortality was higher in African Americans (0.56 percent versus 0.76 percent Caucasians, p=0.012). After 2000, 30-day surgical mortality was equivalent between races (0.46 percent versus 0.35 percent for Caucasians, p=0.517).

Before the year 2000, three-year disease specific survival was better in Caucasians than African Americans (79.3 percent versus 75.1 percent, p=0.025). There was no racial difference in tumor stage (p=0.446) or grade (p=0.495), and African Americans underwent surgical procedures less frequently than Caucasians (p=0.003). Multivariate analysis correcting for patient demographics, socioeconomic status and clinical data demonstrated African American race and failure to undergo surgical treatment were independent predictors of poor prognosis. In patients diagnosed after 2000, three-year disease specific survival was nearly equivalent between Caucasians and African Americans (82.1 percent versus 80.7 percent, p=0.680) and African Americans underwent surgical procedures just as often as Caucasians (p=0.153) did. Multivariate analysis for patients diagnosed after 2000 demonstrated no difference in survival by race (p=0.126).


'/>"/>

Contact: Sally Garneski
pressinquiry@facs.org
312-202-5409
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. Mayo Clinic study continues to refine most effective methods to predict Alzheimers disease
2. Mayo Clinic Study Continues to Refine Most Effective Methods to Predict Alzheimers Disease
3. Reminder program dramatically increases mammography rates, Kaiser Permanente study finds
4. FAIR CEO Blasts Kaiser Foundation & Public Agenda HIV/AIDS Study Results as "Absolute Nonsense"
5. Reminder Program Dramatically Increases Mammography Rates, Kaiser Permanente Study Finds
6. Study estimates radiation dose, cancer risk from coronary artery calcium screening
7. Fluorescent probes may permit monitoring of chemotherapy effectiveness, Stanford study shows
8. Queens University study aims at early diagnosis for ADHD and Parkinsons disease
9. Cats Purrfect at Getting Needs Met, Study Shows
10. Study Evaluating Efficacy and Safety of Two Low-dose Regimens of PREMARIN Vaginal Cream for the Treatment of Moderate to Severe Vaginal Atrophy Now Published
11. Study finds citrus-derived flavonoid prevents obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... medical society dedicated to advancing the science and clinical practice of radiosurgery, ... RSSearch Patient Registry, a multi-institutional, observational registry established to standardize data collection ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a ... Personal Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are ... of their kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way ...
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. ... , Medical doctors and PhD scientists will speak to the press on behalf of ... support of an independent vaccine safety commission. , WHERE: , Zenger Room, National ...
(Date:3/28/2017)... ... 28, 2017 , ... The Radiology Business Management Association (RBMA) is ... its new executive director. Mr. Still was selected through a careful months-long search by ... he is known to our members, has been a part of building the RBMA ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical group ... serving as new board chair for Orange County health care system CalOptima Friday. ... of soon-to-be former chair Mark Refowitz’s term, which runs through June 30 of ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... STRASBOURG, France and TEL AVIV, Israel ... opening a subsidiary in Israel . This new ... , will be mostly dedicated to research and development of novel ... Emosis Ltd will also, when relevant, locally support commercialization and sales ... ...
(Date:3/28/2017)...  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical ... other unmet medical needs, announced today two poster ... annual meeting.  The first poster to be presented ... ENMD-2076 in Combination with Anti-PD1 in Syngeneic Cancer ... presented on April 4 is entitled " Kinase ...
(Date:3/28/2017)... The global flow cytometry ... by 2025, according to a new study by Grand ... and cancer is expected to upsurge the demand for ... coming years. In addition, higher number of physicians is ... cell therapy, due to adverse effects caused by chemotherapy ...
Breaking Medicine Technology: